Biomedical Letters

Endostar as a Perioperative Regimen with Chemotherapy in Osteosarcoma: A Review

Lin Liu *, Nakesh Bhatoolaul

Department of Oncology, Zhong-Da Hospital, School of Medicine, Southeast University, 87 Ding Jia Qiao, Nanjing210009, PR, China.

Abstract: This study was conducted to comprehensively review the efficacy and safety of endostar combined chemotherapy versus chemotherapy alone, for treating osteosarcoma patients. Osteosarcomas, which makes up less than 1% of all cancers in adult and about 13% of sarcomas, can rise from anywhere in the body. The current treatment for osteosarcoma comprises of surgery, radiotherapy and chemotherapy. As for resectable localized osteosarcoma, the standard treatment is surgical resection with adequate margins preserved. Despite of surgery, about half of the patients will suffer from recurrence and metastasis of osteosarcoma, thus requiring systemic chemotherapy as palliative treatment. Apart from Ewing's Sarcoma, osteosarcoma and rhabdomyosarcoma, most sarcomas are not sensitive enough to systemic chemotherapy resulting in cancer progression through blood circulation. Hence, the potential use of anti-angiogenic agent endostar in the treatment of sarcoma is being highly studied in clinical trials. Target therapy drug endostar was found to be both safe and effective when combined with chemotherapy as a perioperative regimen for resect-able advanced osteosarcoma and can benefit patients who cannot tolerate aggressive therapy signifying better tolerability of chemotherapeutic drugs when administered with endostar while also significantly improving the distant metastasis free survival and progression free survival in osteosarcoma patients. Confirmation of these results in larger double blinded controlled randomized trials is necessary before definite conclusions about this therapy can be drawn.

Keywords: Endostar, sarcoma, chemotherapy, Rh-endostatin, therapy.

Received March 14, 2016 Revised April 29, 2016 Accepted May 10, 2016

*Correspondence: Lin Liu Email wenyu811@126.com Contact: +86 13913968688 Fax: +86-027-87543914